Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH

Area of Science:

• Endocrinology
• Genetics
• Pediatrics

Background:

• Prader-Willi syndrome (PWS) is a rare genetic disorder affecting 1 in 10,000-16,000 infants.
• Key features include short stature, hypotonia, developmental delay, behavioral issues, and hyperphagia leading to obesity.
• PWS is often associated with hypothalamic-pituitary dysfunction, specifically growth hormone (GH) deficiency and hypogonadotropic hypogonadism.

Purpose of the Study:

• To evaluate the efficacy and benefits of growth hormone (GH) replacement therapy in children with Prader-Willi syndrome.
• To explore the potential role of sex hormone replacement therapy in managing PWS.

Main Methods:

• Review of clinical trials evaluating GH replacement therapy in children with PWS.
• Analysis of existing data on sex hormone replacement therapy in PWS patients.

Main Results:

• GH treatment demonstrated encouraging results, including improved linear growth and increased lean body mass.
• GH therapy also showed potential benefits in reducing fat mass, improving respiratory function, and enhancing physical activity.
• Limited data exist on the efficacy and long-term benefits of sex hormone replacement therapy.

Conclusions:

• Prader-Willi syndrome is a significant condition characterized by GH deficiency and hypogonadism.
• Active treatment of these endocrine abnormalities, particularly GH replacement, is likely to benefit affected individuals.
• Further research is needed to establish the long-term benefits of GH therapy and clarify the role of sex hormone replacement.